Black and ethnic minorities face inequality in diabetes treatment

Black and ethnic minority people are not as likely to be prescribed newer medication for type 2 diabetes and they experience less adequate monitoring of their condition compared to their white peers, new collaborative research from the University of Surrey and Eli Lilly and Company Limited finds. The study, published in the Journal PLOS Medicine, identified an inequality of care for those with type 2 diabetes from an ethnic minority and those from a socio-economically disadvantaged background. During the study, researchers examined data over a five-year period from 49,380 patients across 164 general practices. Researchers found that black individuals were 50% less